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Abstract
Background: The incidence, prevalence, and molecular epidemiology of urea cycle disorders (UCDs) in Argentina
remain underexplored. The present study is the first to thoroughly assess the clinical and molecular profiles of UCD
patients examined at a single reference center in Argentina.
Results: Forty-nine UCD cases were collected. About half (26/49, 53%) manifested neonatally with classical
presentation and had a high mortality (25/26, 96%). Ornithine transcarbamylase deficiency (OTCD) was the most
common UCD (26 patients). Argininosuccinate synthetase deficiency (ASSD) was detected in 19 cases, while
argininosuccinate lyase deficiency (ASLD) was diagnosed in 4 cases. Molecular genetic analysis revealed 8 private
OTC mutations and two large deletion/duplication events in the OTC gene. Most mutations in the ASS1 and ASL
genes were recurrent missense changes, and four alterations were novel. The clinical outcome of our UCD cohort
was poor, with an overall mortality of 57% (28/49 cases), and a 28% (6/21) disability rate among the survivors.
Conclusions: Most patients in our case series showed severe neonatal onset, with high morbidity/mortality. We
detected in total 19 mutations, most of them recurrent and of high frequency worldwide. Noteworthy, we highlight
the presence of a geographic cluster with high prevalence of a point mutation in the ASS1 gene. This study
suggests that these disorders may be more frequent than commonly assumed, and stresses the need for increased
awareness amongst health professionals and greater availability of diagnostic tools for accurate identification, early
diagnosis, and timely treatment.
Keywords: Urea cycle defects, Hyperammonemia, Ornithine transcarbamylase deficiency, Argininosuccinate
synthetase deficiency, Argininosuccinate lyase deficiency
Synopsis
This is the first case series of urea cycle deficiency patients
from Argentina diagnosed at a single center, describing a
high prevalence of neonatal onset, and confirming high
recurrence of common worldwide mutations plus some pri-
vate mutations first described in our cohort.
Introduction
The urea cycle is the final common pathway for the ex-
cretion of waste nitrogen as well as arginine synthesis
[1]. Urea cycle disorders (UCDs) are inborn errors of am-
monia detoxification/arginine synthesis caused by mutations
in one of five core enzymes, one activating enzyme, or one
of two mitochondrial antiporters. Enzymatic defects include
N-acetylglutamate synthase deficiency (NAGSD;
MIM#237310), carbamoylphosphate synthetase 1 deficiency
(CPS1D; MIM#237300), ornithine transcarbamylase defi-
ciency (OTCD; MIM#311250), argininosuccinate synthetase
deficiency (ASSD; MIM#215700), argininosuccinate lyase
deficiency (ASLD; MIM#207900), and arginase 1 deficiency
(ARG1D; MIM#207800). Two transporters are involved in
the cycle, the ornithine/citrulline antiporter (ORNT1),
associated with the hyperornithinemia-hyperammonemia-
homocitrullinuria (HHH) syndrome (MIM #238970), and
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the glutamate/aspartate antiporter (CITRIN), whose defi-
ciency gives rise to citrullinemia type 2 (MIM #605814 and
#603471). All these deficiencies are inherited in an
autosomal recessive manner, except for OTCD which has
X-linked recessive inheritance, and in some cases arises
from spontaneous mutations in germ cells.
The incidence of UCDs has recently been deter-
mined to be 1 in 35,000 births, although it varies
between populations. About two-thirds of all UCDs
are due to mutations in OTC, while mutations in
ASS1 and ASL account for, one-fifth and one-tenth
of cases, respectively. However, the overall incidence
might be higher because not all cases are detected,
and underdiagnosis of fatal cases is common [2].
The onset and severity of UCDs are highly variable and
depend both on the specific mutation involved and its im-
pact on the corresponding enzymatic or transport function.
The onset of severe forms usually occurs during the neo-
natal period and is characterized by food refusal, vomiting,
lethargy, polypnea, and rapid progression to coma and mul-
tiorgan failure due to hyperammonemia [3, 4]. The onset of
mild forms can occur at any age, with hyperammonemic
episodes triggered during catabolic stress (infections, vomit-
ing, surgery, etc.) or with more insidious symptoms such as
failure to thrive, chronic liver disease, developmental delay,
behavioral disorders, and psychiatric symptoms [5]. Delayed
diagnosis, often as a result of lack of symptom awareness
amongst families and primary health care physicians, results
in either death or cognitive impairment [6].
The Argentinean population is a unique mix of sev-
eral ethnicities, with expected low consanguinity. So
far, only a few UCDs case reports originated from
Argentina [7–9]. The present study summarizes our
experience regarding diagnosis, genetic testing, and
outcomes of 49 UCD patients from 36 families evalu-
ated at a single referral center in Argentina.
Materials and methods
UCD diagnosis
Clinical symptoms of UCD patients included lethargy,
lack of appetite, persistent vomiting, intractable seizures,
unexplained neurological alterations, neurodegeneration,
developmental delay, coma, unexplained recurrent liver
dysfunction, and cholestasis. Samples from subjects with
clinical suspicion of UCD underwent biochemical and
genetic analyses in our laboratory.
Biochemical analyses
A key biomarker for UCDs is hyperammonemia (>
100 μM; > 1 y old) in the absence of high anion gap and
with a normal plasma glucose level. Laboratory findings
characteristic of UCDs include elevated levels of plasma
glutamine and alanine, and high or low plasma concen-
trations of citrulline, arginine and argininosuccinic, wich
allow to determine the enzymatic block of the urea cycle
[4]. Determination of plasma and urinary amino acids
was done using HPLC according to the technique of
Duran et al. (2008) [10]. Quantification of plasma am-
monia was done by enzymatic spectrophotometric assay
(Randox Ammonium Kit, Randox Laboratories LTD,
UK). Measurement of orotic acid in urine by HPLC was
performed according to the technique of Simmonds et
al. (1991, [11]).
Molecular analyses
All subjects, or their parents or legal guardians, pro-
vided consent for DNA testing. Extraction of genomic
DNA was carried out using the purification protocol of
the Wizard Genomic DNA Promega Purification Kit
(Promega, Madison, USA). Genetic analyses consisted
of amplification of the gene/exon of interest from gen-
omic DNA with specific oligonucleotides by PCR, and
examination of the sequence using either restriction en-
zymes or by direct Sanger sequencing (ABI 3130XL
automatic capillary sequencer, Applied Biosystems). If
more extensive gene analysis was needed (i.e. for large
deletions, duplications, or for complete sequencing of
exons and intronic regions) we used Single Strand
Conformational Polymorphism or Multiplex Ligation
dependent Probe Amplification.
Results
Patient series data
Table 1 lists UCDs patient data from our reference
center. It includes 49 cases and their corresponding
clinical presentation, genetic findings, and disease
onset times. OTCD was the most common UCD, ob-
served in 26/49 patients, followed by ASSD, detected
in 19 patients, and by ASLD, diagnosed in 4
patients. About half of the cases (26/49, 53%)
presented in the neonatal period with classical pres-
entation, and had a high mortality (25/26, 96%)
(Additional file 1: Table S1). Plasma ammonia values
for all 49 patients are shown in Fig. 1. Clinical mani-
festations varied, leading to high mortality among
boys diagnosed in the neonatal period or with late-
onset UCD forms, and included also asymptomatic
and severely affected women. Symptoms began in
the neonatal period in 55% (5/9) of cases in hemizy-
gous males; neonatal forms were not observed in
symptomatic carriers, but late-onset disease was
present in 43% (7/17) of the female cases (Fig. 2).
Besides hyperammonemia as main diagnostic bio-
marker, the patient series presented high levels of urinary
orotic acid (average 1733 μmol/mmol creatinine, range
117–6879 μmol/mmol creatinine, NV < 10 μmol/mmol
creatinine [10]). This confirmed that the enzyme block
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Table 1 CEMECO’s UCDs cohort description
Fam Pat Presentation Gene Alteration Protein Onset Remarks
I 1 Symptomatic female OTC delExon1–10 7 m ND †
2 Symptomatic female OTC delExon 1–10 3y ND, DA
3 Hemizygous neonatal onset OTC delExon 1–10 5d ND †
4 Asymptomatic female OTC delExon1–10
5 Asymptomatic female OTC delExon1–10
II 6 Hemizygous late onset OTC c.216 + 1G > A Affects splicing 2y
7 Asymptomatic female OTC c.216 + 1G > A Affects splicing
III 8 Hemizygous late onset OTC c.386G > A Affects splicing 6 m ND
9 Asymptomatic female OTC c.386G > A Affects splicing
IV 10 Symptomatic female OTC c.452 T > G p.Leu151Arg 4y ND
V 11 Symptomatic female OTC c.533C > T p.Thr178Met 10 m ND
12 Hemizygous neonatal onset OTC c.533C > T p.Thr178Met 48-72hs ND †
13 Asymptomatic female OTC c.533C > T p.Thr178Met
VI 14 Symptomatic female OTC c.540 + 1G > A Intronic 9 m ND
VII 15 Hemizygous neonatal onset OTC c.540 + 1G > A Intronic 48-72hs
16 Asymptomatic female OTC c.540 + 1G > A Intronic
VIII 17 Hemizygous late onset OTC c.622G > A p.Ala208Thr 8y
18 Asymptomatic female OTC c.622G > A p.Ala208Thr
IX 19 Hemizygous late onset OTC c.829C > T p.Arg277Trp 10y †
20 Asymptomatic female OTC c.829C > T p.Arg277Trp
X 21 Symptomatic female OTC dup1–9/del10 – 9 m †
XI 22 Hemizygous neonatal onset OTC c.697delG p.Ala233Glnfs*14 48-72hs †
23 Asymptomatic female OTC c.697delG p.Ala233Glnfs*14
24 Asymptomatic female OTC c.697delG p.Ala233Glnfs*14
XII 25 Hemizygous neonatal onset OTC NA NA 48-72hs †
XIII 26 Symptomatic female OTC NA NA 48-72hs †
XIV 27 Late ASS1 c.79 T > C / c.847G > A p.Gln27* / p.Glu283Lys 45d
XV 28 Late ASS1 c.79 T > C / c.970G > A p.Gln27* / p.Gly324Ser 16d †
XVI 29 Neonatal ASS1 c.1168G > A /c.1168G > A p.Gly390Arg /p.Gly390Arg 48-72hs †
XVII 30 Neonatal ASS1 c.1168G > A /c.1168G > A p.Gly390Arg /p.Gly390Arg 48-72hs †
XVIII 31 Neonatal ASS1 c.1168G > A /c.1168G > A p.Gly390Arg /p.Gly390Arg 48-72hs †
XIX 32 Neonatal ASS1 c.1168G > A /c.1168G > A p.Gly390Arg /p.Gly390Arg 48-72hs †
XX 33 Neonatal ASS1 c.1168G > A /c.1168G > A p.Gly390Arg /p.Gly390Arg 48-72hs †
XXI 34 Neonatal ASS1 c.1168G > A /c.1168G > A p.Gly390Arg /p.Gly390Arg 48-72hs †
XXII 35 Neonatal ASS1 c.1168G > A /c.1168G > A p.Gly390Arg /p.Gly390Arg 48-72hs †
XXIII 36 Neonatal ASS1 c.1168G > A /c.1168G > A p.Gly390Arg /p.Gly390Arg 48-72hs †
XXIV 37 Neonatal ASS1 c.1168G > A /c.1168G > A p.Gly390Arg /p.Gly390Arg 48-72hs †
XXV 38 Neonatal ASS1 c.1168G > A /c.1168G > A p.Gly390Arg /p.Gly390Arg 48-72hs †
XXVI 39 Neonatal ASS1 c.1168G > A /c.1168G > A p.Gly390Arg /p.Gly390Arg 48-72hs †
XXVII 40 Neonatal ASS1 c.1168G > A /c.1168G > A p.Gly390Arg /p.Gly390Arg 48-72hs †
XXVIII 41 Neonatal ASS1 c.1168G > A /c.1168G > A p.Gly390Arg /p.Gly390Arg 48-72hs †
XXIX 42 Neonatal ASS1 c.1168G > A /c.1168G > A p.Gly390Arg /p.Gly390Arg 48-72hs †
XXX 43 Neonatal ASS1 c.1168G > A /c.1168G > A p.Gly390Arg /p.Gly390Arg 48-72hs †
XXXI 44 Neonatal ASS1 c.1168G > A /c.1168G > A p.Gly390Arg /p.Gly390Arg 48-72hs †
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was downstream of CPS1, thus ruling out possible CPS1D
or NAGSD.
Ornithine transcarbamylase deficiency
A total of 26 patients belonging to 12 families were diag-
nosed with OTCD; 17/26 were women and 9/26 were
men. The mean age of onset of symptoms was 29.9
months (48 h-10 years). Whereas neurological damage
was present in most cases, disease manifestations some-
times differed among patients with the same mutation.
For OTCD patients mean ammonia level at the begin-
ning of the symptoms was 778.1 μmol/L (range: 98–2181;
Fig. 1), mean glutamine levels were also elevated
(2065 μmol/L; range: 277–4229), while citrulline and ar-
ginine values were within normal range (Table 2).
We were able to determine the disease-causing mutation
in all but two patients, as we lost contact with their parents
and could not obtain the respective DNA samples. The
alterations found in the other 24 patients, and their clinical
presentations, are listed in Table 1. These included: 4
hemizygotes with neonatal onset (complete OTC gene dele-
tion, c.533C >T, c.540 + 1G >A, c.697delG); 4 hemizygotes
with late onset (c.216 + 1G >A, c.386G >A, c.622G >A,
c.829C >T); 6 symptomatic heterozygotes (complete OTC
gene deletion, c.533C >T, c.452 T >G, c.540 + 1G >A,
dupE1–9/delE10); and 10 asymptomatic females with an al-
most complete representation of the mutational spectrum
within this cohort, implying a more favorable lyonization in
these patients.
Argininosuccinate synthetase deficiency
Nineteen patients belonging to 19 families were identified
with ASSD (11 females, 57.9%; 8 males, 42.1%) (Table 1).
Neonatal forms were detected in all but two cases.
Severe disease manifestation, characterized by symp-
toms in the first hours of life and death in the neonatal
period, predominated in this cohort. The two other cases,
detected at 45 and 16 days of life, progressed with severe
hyperammonemic crisis and metabolic decompensation
(Fig. 2). Cognitive and developmental deterioration could
Table 1 CEMECO’s UCDs cohort description (Continued)
Fam Pat Presentation Gene Alteration Protein Onset Remarks
XXXII 45 Neonatal ASS1 c.1168G > A /c.1168G > A p.Gly390Arg /p.Gly390Arg 48-72hs †
XXXIII 46 Neonatal ASL c.857A > G/c.328G > T p.Gln286Arg/p.Gly110* 48-72hs †
XXXIV 47 Late ASL c.857A > G/c.436C > T p.Gln286Arg/p.Arg146Trp 20 m
XXXV 48 Neonatal ASL c.857A > G/c.857A > G p.Gln286Arg/p.Gln286Arg 48-72hs ND
XXXVI 49 Neonatal ASL c.857A > G/c.857A > G p.Gln286Arg/p.Gln286Arg 48-72hs †
ND Neurologic damage, †: deceased; DA Diagnosis in asymptomatic period, NA Not assessed
Fig. 1 Plasma ammonia levels at UCDs diagnosis. Grey dotted lines indicate normal plasma ammonia (bottom: upper limit in children > 1 year
old) and recommended value for hemodialysis (top; [22]). Black solid lines indicate mean values for each UCD
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be observed in one of these patients (patient 28), who died
at 18months.
Mean ammonia level at the onset of ASSD symp-
toms was 1017 μmol/L (range: 399–1600; Fig. 1),
while mean glutamine level (2863 μmol/L; range:
1123-4504; Table 2) was higher than in OTCD due
to the large number of severe neonatal cases of
ASSD. Characteristically, ASSD patients had highly
increased plasma citrulline (3203 μmol/L; range:
758–8500), while arginine levels were below the nor-
mal range (12.9 μmol/L; range: 8.0–25.2) (Table 2).
Exact determination of the ASS1 genotype could be
achieved in all patients, in many cases deductively from
the DNA of parents heterozygous for the molecular de-
fect. Thus, genetic screening of the 19 affected families
allowed us to identify the alterations described in Table 1.
Among those families, 17 presented the same mutation in
homozygosity, namely c.1168G >A (p.Gly390Arg), and 2
nonrelated families carried the same recurrent mutation,
c.79 T > C (p.Gln27*), in heterozygosity. The other two
mutations found in these compound heterozygotes were
two previously reported missense changes: c.847G >A
(p.Glu283Lys) and c.970G > A (p.Gly324Ser) [12, 13].
Argininosuccinate lyase deficiency
Four patients from 4 families (1 woman and 3 males)
were identified with ASLD (Table 1). The mean age
at onset of symptoms was 2 days in the 3 neonatal
forms, with two deaths registered in the neonatal
period, and 20 months in the late-onset form. The lat-
ter patient showed no severe hyperammonemic crisis
or metabolic decompensation, and the main clinical
features were hypotonia and trichorrhexis nodosa with
baldness periods. Cognitive and developmental deteri-
oration could be observed in one of the patients with
neonatal onset (patient 48).
For all ASLD patients average ammonia level at the
onset of symptoms was 478 μmol/L (range: 133–1035;
Fig. 1). Glutamine was also elevated (1346 μmol/L;
range: 374–2913; Table 2). Argininosuccinate levels
were, as expected for ASLD, extremely high (80 μmol/
L; range: 37–179), while arginine levels were within
normal range (Table 2).
Molecular assays on the ASL gene allowed us to de-
termine the specific causal mutations and establish
accurate diagnoses. The mutations found were
c.328G > T (p.Gly110*), c.436C > T (p.Arg146Trp), and
Fig. 2 UCDs’ onset. Grayscale stacked bars indicate the number of cases with neonatal, late-onset, or asymptomatic presentation in each disease.
OTCD asymptomatic females are shown as a separate group and described in the text
Table 2 Mean values and ranges (μmol/L) of plasma metabolites in UCD patients
Disease Ammonia Glutamine Citrulline Arginine Argininosuccinate
Control < 100 333–809 16–32 44–120 0–0.7
OTCD 778.1 (98–2181) 2065.44 (277–4229) 14.6 (0–28) 66.0 (8–135) –
ASSD 1017.1 (399–1600) 2863.24 (1123-4504) 3203.8 (758–8500) 12.9 (8–25.2) –
ASLD 478.3 (133–1035) 1346.32 (374–2913) 222.3 (75–357) 10.7 (4–23) 80.7 (37–179)
Control: Reference values and ranges for pediatric population (> 1 year old) [10]
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c.857A > G (p.Gln286Arg), all previously reported in
the literature [14, 15].
Discussion
This study reports the first comprehensive case series of
UCDs in Argentina. Using the latest estimated incidence
of UCDs of 1 in 35,000 [2], and a birth rate of 457,335
live births per year in Argentina (Censo Nacional de
Población, Hogares y Viviendas 2010), an average of 13
new UCDs patients can be expected each year in
Argentina. Summar et al. (2013) [2] reported that 26% of
patients were symptomatic in the newborn period and
69% of all patients had symptoms at some point. This
should result in a minimum of 9 UCDs patients with
hyperammonemia per year in Argentina, 4 of them pre-
senting neonatal onset. However, the average incidence
calculated from national registries is 4 new UCDs pa-
tients per year. We speculate that more patients may be
diagnosed at other clinics and medical centers in
Argentina and not being reported, but is also likely that
many cases are not being correctly identified.
Onset and follow up
We found several precipitating factors of hyperammone-
mic crises in our UCD patient cohort, among them
abandonment of diet and/or pharmacological treatment,
and infectious processes; these increased morbidity
markers, hospitalization rates and lengths of stay, and
led to a greater use of ammonium chelators. The mortal-
ity rate in our cohort (53%) is higher than reported for
similar case series. A possible explanation may be the
high prevalence of neonatal onset citrullinemia in a cir-
cumscribed area, added to underreporting of mild cases
in our population. Notwithstanding, the data from this
study confirm that neonatal onset UCD patients are at
high risk for not only initial life-threatening decompen-
sation but also for recurrent hyperammonemic crises
and peak ammonia values, which may result in perman-
ent neurological damage [16]. Of note, the presence of
high ammonia levels in symptomatic females or late-on-
set forms, indicates that late forms are not always mild.
Since the severity of the crisis is multifactorial, pheno-
type prediction is important to prevent and effectively
manage future crises.
Treatment and follow-up of UCD symptomatic patients
in our center follows international guidelines with respect
to diet, supplements, and medication [3]. Additional
adverse factors in developing countries like Argentina are
inadequate facilities in most primary and secondary level
hospitals that contribute to poor outcomes. For instance,
laboratory ammonia assays are usually available only in ter-
tiary hospitals. Therefore, patients may die without a diag-
nosis, or the disease is diagnosed late, contributing to
increased morbidity and mortality. Identification of UCDs
in the affected families allowed accurate retrospective diag-
noses and medical advice to parents regarding future preg-
nancies. Meanwhile, early diagnosis meant an integral
improvement in the quality of life of patients, by imple-
menting timely and adequate treatment and follow-ups.
Mutation Spectrum
Our previous report assessed three unreported OTCD-
causing mutations: c.540 + 1G > A, c.697delG, and
dup1–9/del10, and highlighted the relevance of
combining molecular and bioinformatics analyses for
accurate diagnosis and outcome prediction in patients
with suspected OTCD [9]. We matched clinical, bio-
chemical, and molecular findings with bioinformatics
analyses to report genotype-phenotype correlations in
this OTCD case series [9].
We found four ASS1 mutations in our population: c.79
T >C (p.Gln27*), c.847G >A (p.Glu283Lys), c.970G >A
(p.Gly324Ser) and c.1168G >A (p.Gly390Arg). The muta-
tion c.79 T >C (p.Gln27*) was first described in our popula-
tion and blocks the enzymatic activity of ASS by producing
a stop codon in exon 3; this variant was recently found as-
sociated with severe neonatal onset in an Arab homozygous
patient [17]. It should be noted that two patients in our
group presented this mutation although there is no rela-
tionship between these patients, nor known consanguinity
between parents. The c.847G >A (p.Glu283Lys) mutation
described by Gao et al. (2003) [13] in a homozygous patient
produces a severe phenotype. The coexistence of this muta-
tion with the c.79 T >C mutated allele in patient 27 gener-
ates a significant structural change in the enzyme,
explaining the clinical presentation of the child, i.e. protein
intolerance and frequent metabolic decompensation despite
treatment with high doses of sodium phenylbutyrate. The
missense mutation c.970G >A (p.Gly324Ser) described by
Kobayashi et al. (1990) [14] has been identified exclusively
in patients with a severe phenotype. The G324 residue is
strictly conserved in all reported homologous sequences of
ASS. This substitution breaks the helical structure of α-
helix 10, preventing the binding of citrulline and aspartate
[17]. In vitro bacterial expression systems used to validate
this mutation show a null ASS activity [18]. It is speculated
that the coexistence of these two mutated alleles (c.79 T >
C / c.970G >A) in patient 28 generates a significant struc-
tural change in the enzyme. This is expected to aggravate
clinical evolution, but besides protein intolerance and sig-
nificant psychomotor-cognitive delay, there are rare meta-
bolic decompensations under treatment with sodium
benzoate and good management of plasma ammonia levels.
At 18months of age this patient had a hyperammonemic
crisis (peak ammonia = 480 μmol/L) concurrent with hypo-
tonia, epilepsy, vomiting, and respiratory distress, and died
after 5 days of hospitalization despite intensive care
measures.
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The c.1168G >A (p.Gly390Arg) mutation found in the
majority of patients of this cohort was previously described
by Engel et al. (2009) [19] with high prevalence worldwide.
This alteration represented 88.8% of all the mutated ASS1
alleles in our ASSD cohort, a rate higher than the 27–62.5%
described globally by Diez-Fernandez (2017) [16]; the car-
rier frequency of p.Gly390Arg is 4.1% or 1/25 inhabitants;
however, the incidence of ASSD in our center, of 1 in 2427
children [7], is approximately twenty times higher than the
worldwide incidence of 1 in 57,000 reported by Brusilow
and Horwich (2001) [1], and for this reason this substitu-
tion was specifically assessed by our group [7]. Genealogy
analysis of several affected families suggests a transmission
ratio distortion of the mutated allele compared to the ex-
pected frequency [20, 21]; thus, occurrence of the disease in
descendants of couples at risk is 57.89%, i.e. more than
twice the frequency expected for an autosomal recessive
disease. Due to the high incidence of ASSD in our country,
we proposed that preconceptional diagnosis of carriers is
the most rational preventive measure for the management
of ASSD, for which there is still no effective treatment [7].
The mutations in the ASL gene were c.328G > T
(p.Gly110*), c.436C > T (p.Arg146Trp), and c.857A > G
(p.Gln286Arg), all previously reported in the literature
[14, 15]. The mutation p.Gln286Arg variant has a
high frequency worldwide and was the subject of
many studies for its capacity for intragenic comple-
mentation. All the alterations found are severe, caus-
ing lack of ASL activity, but due to the intragenic
complementation phenomenon, the patient that is
compound heterozygous for c.857A > G/c.436C > T
(patient 47) had late-onset and presented minimal
manifestations of the deficiency (Table 1).
Conclusion
This is the first comprehensive report of mutations in UCDs
from Argentina. However, because our study is restricted to
patients diagnosed in a single reference center, it may not be
representative of the overall incidence of UCDs in the coun-
try. To improve the prognosis of these patients it would be
of great importance to expand neonatal screening for UCDs,
incorporating newer diagnostic and therapeutic tools, and to
create a national UCD registry to know the true incidence
of these diseases. Likewise, educating pediatricians, neurolo-
gists, and neonatologists about UCDs and their symptoms
will allow to diagnose more patients at a presymptomatic
state or when ammonia levels are still below the threshold
that causes irreversible neurological damage.
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